BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today
Arcos Dorados Holdings (NYSE:ARCO) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 100 percent. This is a 185.71 percent increase over losses of $(0.14) per share from